查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1566359

血漿蛋白分解酵素C1抑制劑市場，規模，佔有率，趨勢，產業分析報告:各類藥物，各劑型，各流通管道，各地區 - 市場預測，2024年～2032年

Plasma Protease C1-inhibitor Market Size, Share, Trends, and Industry Analysis Report: By Drug Class, Dosage Form, Distribution Channel, and Region - Market Forecast, 2024 - 2032
出版日期: | 出版商: Polaris Market Research | 英文 117 Pages | 商品交期: 最快1-2個工作天內

價格

根據 Polaris Market Research 的最新研究，血漿蛋白酶 C1 抑制劑的全球市場預計到 2032 年將達到 79.6 億美元。該報告提供了對當前市場動態的詳細見解，並對未來市場成長進行了分析。

血漿蛋白酶 C1 抑制劑 (C1-INH) 市場近年來由於配方、安全性、治療功效和適應症的擴大而經歷了重大的技術創新。從靜脈注射轉向皮下注射代表了重大飛躍，提供了更大的便利性並可能提高患者的依從性。同時，純化製程的改進提高了 C1-INH 製劑的安全性，最大限度地減少副作用並最大限度地提高治療效果。

對傳統 C1-INH 替代療法以外的新作用機制的持續研究可能會擴大治療選擇，並解決更廣泛的遺傳性血管水腫 (HAE) 和相關疾病患者的問題。例如，根據阿姆斯特丹 UMC 內科醫生和研究人員報道，2024 年 6 月，兩種新藥 donidalorsen 和 sevetralstat 在治療遺傳性血管水腫方面顯示出有希望的結果。

血漿蛋白酶 C1 抑制劑 (C1-INH) 市場的特徵是全球 HAE 診斷增加推動需求不斷增長。這種罕見的遺傳疾病需要有效的 C1-INH 替代療法，促使治療方案不斷進步。給藥方法和配方的創新旨在提高患者的便利性和依從性，而地理擴張的目標是改善全球這些特殊療法的可及性。競爭格局依然活躍，製藥公司投資於研發，並得到促進市場成長和新療法採用的監管措施的支持。以患者為中心的計劃和宣傳工作進一步有助於改善 HAE 患者的治療結果和生活質量，塑造 C1-INH 市場的未來軌跡。

血漿蛋白酶 C1 抑制劑市場報告重點

C1 抑制劑預計將在 2023 年引領市場，由於關鍵參與者的持續研發努力，選擇性緩激肽 B2 受體拮抗劑預計將顯示出最快的成長。

冷凍乾燥製劑因其穩定性、延長的保質期以及方便的儲存和運輸而成為 C1 抑制劑治療的首選，並且由於其能夠確保患者和醫療保健提供者的療效和便利性而獲得市場動力。

醫院藥局因其廣泛的可及性、法規遵循以及對血漿蛋白酶 C1 抑制劑等特殊療法的有效管理而引領血漿蛋白酶 C1 抑制劑市場。

由於高額醫療支出、先進的基礎設施、廣泛的研究以及血漿蛋白酶 C1 抑制劑治療遺傳性血管性水腫等罕見疾病的大量使用，北美將在 2023 年引領市場。

全球領先的血漿蛋白酶 C1 抑制劑公司包括 BioCryst Pharmaceuticals, Inc.、CENTOGENE NV、CSL、Fresenius Kabi、Ionis Pharmaceuticals, Inc.、KalVista Pharmaceuticals、Pharming、Sanquin、Shire plc 和 Takeda Pharmaceuticals。

目錄

第1章 簡介

第2章 摘要整理

第3章 調查手法

第4章 全球血漿蛋白分解酵素C1抑制劑市場洞察

  • 應用概述
  • 血漿蛋白分解酵素C1抑制劑市場動態
    • 促進因素和機會
      • 臨床試驗和研究活動的增加推動市場成長
      • 醫療保健領域支出的增加推動血漿蛋白酶 C1 抑制劑市場成長
    • 阻礙因素與課題
      • 治療費的急劇上升
  • PESTEL分析
  • 血漿蛋白分解酵素C1抑制劑市場應用趨勢
  • 價值鏈分析
  • COVID-19影響分析

第5章 全球血漿蛋白分解酵素C1抑制劑市場:各類藥物

  • 主要調查結果
  • 簡介
  • C1抑制劑
  • 激肽釋放酶抑制劑
  • 選擇性緩激肽 B2 受體拮抗劑

第6章 全球血漿蛋白分解酵素C1抑制劑市場:各劑型

  • 主要調查結果
  • 簡介
  • 冷凍乾燥
  • 注射劑

第7章 全球血漿蛋白分解酵素C1抑制劑市場:各流通管道

  • 主要調查結果
  • 簡介
  • 醫院藥局
  • 零售藥局
  • 線上藥局

第8章 全球血漿蛋白分解酵素C1抑制劑市場:各地區

  • 主要調查結果
  • 簡介
    • 血漿蛋白分解酵素C1抑制劑市場評估:地區，2019年～2032年
  • 北美
    • 北美:各類藥物，2019年～2032年
    • 北美:各劑型，2019年～2032年
    • 北美:各流通管道，2019年～2032年
    • 美國
    • 加拿大
  • 歐洲
    • 歐洲:各類藥物，2019年～2032年
    • 歐洲:各劑型，2019年～2032年
    • 歐洲:各流通管道，2019年～2032年
    • 英國
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 荷蘭
    • 俄羅斯
    • 其他歐洲
  • 亞太地區
    • 亞太地區:各類藥物，2019年～2032年
    • 亞太地區:各劑型，2019年～2032年
    • 亞太地區:各流通管道，2019年～2032年
    • 中國
    • 印度
    • 馬來西亞
    • 日本
    • 印尼
    • 韓國
    • 澳洲
    • 其他亞太地區
  • 中東·非洲
    • 中東·非洲:各類藥物，2019年～2032年
    • 中東·非洲:各劑型，2019年～2032年
    • 中東·非洲:各流通管道，2019年～2032年
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 南非
    • 其他中東和非洲
  • 南美
    • 南美:各類藥物，2019年～2032年
    • 南美:各劑型，2019年～2032年
    • 南美:各流通管道，2019年～2032年
    • 墨西哥
    • 巴西
    • 阿根廷
    • 其他南美國家

第9章 競爭情形

  • 擴大和收購的分析
    • 擴大
    • 收購
  • 聯盟/合作/協定/公開

第10章 企業簡介

  • BioCryst Pharmaceuticals, Inc.
  • CENTOGENE N.V.
  • CSL
  • Fresenius Kabi
  • Ionis Pharmaceuticals, Inc.
  • KalVista Pharmaceuticals
  • Pharming
  • Sanquin
  • Shire plc
  • Takeda Pharmaceutical Company Limited
Product Code: PM5058

The global plasma protease C1-inhibitor market size is expected to reach USD 7.96 billion by 2032, according to a new study by Polaris Market Research. The report "Global Plasma Protease C1-inhibitor Market Size, Share, Trends, Industry Analysis Report: By Drug Class (C1-inhibitors, Kallikrein Inhibitor, and Selective Bradykinin B2 Receptor), Dosage Form, Distribution Channel, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2024 - 2032." gives a detailed insight into current market dynamics and provides analysis on future market growth.

The market for plasma protease C1-inhibitor (C1-INH) has witnessed substantial innovation in recent years, driven by advancements in formulation, safety, therapeutic efficacy, and expanded indications. The shift from intravenous to subcutaneous administration represents a significant leap forward, offering improved convenience and potentially enhancing patient compliance. Concurrently, improvements in purification processes have bolstered the safety profiles of C1-INH products, minimized adverse reactions and maximizing therapeutic effectiveness.

Ongoing research into novel mechanisms of action beyond traditional C1-INH replacement therapy holds promise for broadening treatment options, potentially catering to a wider range of patients with hereditary angioedema (HAE) and related conditions. For instance, in June 2024, two new medicines, donidalorsen and sebetralstat, showed promising results in treating hereditary angioedema, as reported by an internist and researcher from Amsterdam UMC.

The market for plasma protease C1-inhibitor (C1-INH) is characterized by a rising demand driven by increasing diagnoses of HAE globally. This rare genetic disorder necessitates effective C1-INH replacement therapies, prompting ongoing advancements in treatment options. Innovations in delivery methods and formulations aim to enhance patient convenience and adherence, while geographic expansion efforts seek to improve access to these specialized therapies worldwide. The competitive landscape remains active with pharmaceutical companies investing in research and development, supported by regulatory initiatives that facilitate market growth and adoption of new therapies. Patient-centric programs and advocacy efforts further contribute to improving outcomes and quality of life for individuals living with HAE, shaping the future trajectory of the C1-INH market.

Plasma Protease C1-inhibitor Market Report Highlights

C1-inhibitors led the market in 2023, with selective bradykinin B2 receptor antagonists expected to show the fastest growth due to ongoing R&D efforts by key industry players.

Lyophilized segments dominated the market with their stability, extended shelf life, and convenient storage and transport, making them favored for C1-inhibitor therapy, ensuring effectiveness and ease for patients and providers.

Hospital pharmacies led the plasma protease C1-inhibitor market due to their wide accessibility, regulatory adherence, and effective management of specialized therapies such as plasma protease C1-inhibitor.

North America led the market in 2023, owing to its substantial healthcare spending, advanced infrastructure, extensive research, and significant use of plasma protease C1-inhibitor therapies for rare diseases such as hereditary angioedema.

The global key plasma protease C1-inhibitor market players include BioCryst Pharmaceuticals, Inc.; CENTOGENE N.V.; CSL; Fresenius Kabi; Ionis Pharmaceuticals, Inc.; KalVista Pharmaceuticals; Pharming; Sanquin; Shire plc; and Takeda Pharmaceutical Company Limited.

Polaris Market Research has segmented the Plasma Protease C1-inhibitor market report based on drug class, dosage form, distribution channel, and region:

By Drug Class Outlook (Revenue - USD billion, 2019 - 2032)

  • C1-inhibitors
  • C1-esterase Inhibitor
  • Recombinant Inhibitor
  • Kallikrein Inhibitor
  • Selective Bradykinin B2 Receptor Antagonist

By Dosage Form Outlook (Revenue - USD billion, 2019 - 2032)

  • Lyphophlised
  • Injectables

By Distribution Channel Outlook (Revenue - USD billion, 2019 - 2032)

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Regional Outlook (Revenue - USD billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Australia
  • Vietnam
  • Rest of Asia Pacific
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Plasma Protease C1-inhibitor Market Insights

  • 4.1. Plasma Protease C1-inhibitor Market - Application Snapshot
  • 4.2. Plasma Protease C1-inhibitor Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increasing Clinical Trials and Research Initiatives is Driving the Market Growth
      • 4.2.1.2. Rising Expenditure in Healthcare Sector Driving Plasma Protease C1-Inhibitor Market Growth
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High Cost of Treatment
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Plasma Protease C1-inhibitor Market Application Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Plasma Protease C1-inhibitor Market, by Drug Class

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
  • 5.3. C1-Inhibitor
    • 5.3.1. Global Plasma Protease C1-inhibitor Market, by C1-Inhibitor, by Region, 2019-2032 (USD billion)
      • 5.3.1.1 C1-esterase Inhibitor
      • 5.3.1.1.1 Global Plasma Protease C1-inhibitor Market, by C1-esterase Inhibitor, by Region, 2019-2032 (USD billion)
      • 5.3.1.2 Recombinant Inhibitor
      • 5.3.1.1.2 Global Plasma Protease C1-inhibitor Market, by Recombinant Inhibitor, by Region, 2019-2032 (USD billion)
  • 5.4. Kallikrein Inhibitor
    • 5.4.1. Global Plasma Protease C1-inhibitor Market, by Kallikrein Inhibitor, by Region, 2019-2032 (USD billion)
  • 5.5. Selective Bradykinin B2 Receptor Antagonist
    • 5.5.1. Global Plasma Protease C1-inhibitor Market, by Selective Bradykinin B2 Receptor Antagonist, by Region, 2019-2032 (USD billion)

6. Global Plasma Protease C1-inhibitor Market, by Dosage Form

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
  • 6.3. Lyphophlised
    • 6.3.1. Global Plasma Protease C1-inhibitor Market, by Lyphophlised, by Region, 2019-2032 (USD billion)
  • 6.4. Injectables
    • 6.4.1. Global Plasma Protease C1-inhibitor Market, by Injectables, by Region, 2019-2032 (USD billion)

7. Global Plasma Protease C1-inhibitor Market, by Distribution Channel

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • 7.3. Hospital Pharmacies
    • 7.3.1. Global Plasma Protease C1-inhibitor Market, by Hospital Pharmacies, By Region, 2019-2032 (USD billion)
  • 7.4. Retail Pharmacies
    • 7.4.1. Global Plasma Protease C1-inhibitor Market, by Retail Pharmacies, By Region, 2019-2032 (USD billion)
  • 7.5. Online Pharmacies
    • 7.5.1. Global Plasma Protease C1-inhibitor Market, by Online Pharmacies, By Region, 2019-2032 (USD billion)

8. Global Plasma Protease C1-inhibitor Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Plasma Protease C1-inhibitor Market Assessment, By Geography, 2019-2032 (USD billion)
  • 8.3. Plasma Protease C1-inhibitor Market - North America
    • 8.3.1. North America: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
    • 8.3.2. North America: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
    • 8.3.3. North America: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
    • 8.3.4. Plasma Protease C1-inhibitor Market - U.S.
      • 8.3.4.1. U.S.: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
      • 8.3.4.2. U.S.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
      • 8.3.4.3. U.S.: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
    • 8.3.5. Plasma Protease C1-inhibitor Market - Canada
      • 8.3.5.1. Canada: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
      • 8.3.5.2. Canada.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
      • 8.3.5.3. Canada: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • 8.4. Plasma Protease C1-inhibitor Market - Europe
    • 8.4.1. Europe: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
    • 8.4.2. Europe.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
    • 8.4.3. Europe: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
    • 8.4.4. Plasma Protease C1-inhibitor Market - UK
      • 8.4.4.1. UK: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
      • 8.4.4.2. UK.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
      • 8.4.4.3. UK: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
    • 8.4.5. Plasma Protease C1-inhibitor Market - France
      • 8.4.5.1. France: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
      • 8.4.5.2. France.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
      • 8.4.5.3. France: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
    • 8.4.6. Plasma Protease C1-inhibitor Market - Germany
      • 8.4.6.1. Germany: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
      • 8.4.6.2. Germany.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
      • 8.4.6.3. Germany: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
    • 8.4.7. Plasma Protease C1-inhibitor Market - Italy
      • 8.4.7.1. Italy: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
      • 8.4.7.2. Italy.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
      • 8.4.7.3. Italy: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
    • 8.4.8. Plasma Protease C1-inhibitor Market - Spain
      • 8.4.8.1. Spain: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
      • 8.4.8.2. Spain.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
      • 8.4.8.3. Spain: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
    • 8.4.9. Plasma Protease C1-inhibitor Market - Netherlands
      • 8.4.9.1. Netherlands: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
      • 8.4.9.2. Netherlands.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
      • 8.4.9.3. Netherlands: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
    • 8.4.10. Plasma Protease C1-inhibitor Market - Russia
      • 8.4.10.1. Russia: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
      • 8.4.10.2. Russia.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
      • 8.4.10.3. Russia: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
    • 8.4.11. Plasma Protease C1-inhibitor Market - Rest of Europe
      • 8.4.11.1. Rest of Europe: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
      • 8.4.11.2. Rest of Europe.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
      • 8.4.11.3. Rest of Europe: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • 8.5. Plasma Protease C1-inhibitor Market - Asia Pacific
    • 8.5.1. Asia Pacific: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
    • 8.5.2. Asia Pacific.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
    • 8.5.3. Asia Pacific: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
    • 8.5.4. Plasma Protease C1-inhibitor Market - China
      • 8.5.4.1. China: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
      • 8.5.4.2. China.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
      • 8.5.4.3. China: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
    • 8.5.5. Plasma Protease C1-inhibitor Market - India
      • 8.5.5.1. India: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
      • 8.5.5.2. India.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
      • 8.5.5.3. India: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
    • 8.5.6. Plasma Protease C1-inhibitor Market - Malaysia
      • 8.5.6.1. Malaysia: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
      • 8.5.6.2. Malaysia.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
      • 8.5.6.3. Malaysia: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
    • 8.5.7. Plasma Protease C1-inhibitor Market - Japan
      • 8.5.7.1. Japan: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
      • 8.5.7.2. Japan.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
      • 8.5.7.3. Japan: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
    • 8.5.8. Plasma Protease C1-inhibitor Market - Indonesia
      • 8.5.8.1. Indonesia: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
      • 8.5.8.2. Indonesia.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
      • 8.5.8.3. Indonesia: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
    • 8.5.9. Plasma Protease C1-inhibitor Market - South Korea
      • 8.5.9.1. South Korea: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
      • 8.5.9.2. South Korea: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
      • 8.5.9.3. South Korea: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
    • 8.5.10. Plasma Protease C1-inhibitor Market - Australia
      • 8.5.10.1. Australia: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
      • 8.5.10.2. Australia: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
      • 8.5.10.3. Australia: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
    • 8.5.11. Plasma Protease C1-inhibitor Market - Rest of Asia Pacific
      • 8.5.11.1. Rest of Asia Pacific: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
      • 8.5.11.2. Rest of Asia Pacific: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
      • 8.5.11.3. Rest of Asia Pacific: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • 8.6. Plasma Protease C1-inhibitor Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
    • 8.6.2. Middle East & Africa.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
    • 8.6.3. Middle East & Africa: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
    • 8.6.4. Plasma Protease C1-inhibitor Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
      • 8.6.4.2. Saudi Arabia.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
      • 8.6.4.3. Saudi Arabia: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
    • 8.6.5. Plasma Protease C1-inhibitor Market - UAE
      • 8.6.5.1. UAE: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
      • 8.6.5.2. UAE.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
      • 8.6.5.3. UAE: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
    • 8.6.6. Plasma Protease C1-inhibitor Market - Israel
      • 8.6.6.1. Israel: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
      • 8.6.6.2. Israel.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
      • 8.6.6.3. Israel: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
    • 8.6.7. Plasma Protease C1-inhibitor Market - South Africa
      • 8.6.7.1. South Africa: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
      • 8.6.7.2. South Africa.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
      • 8.6.7.3. South Africa: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
    • 8.6.8. Plasma Protease C1-inhibitor Market - Rest of Middle East & Africa
      • 8.6.8.1. Rest of Middle East & Africa: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
      • 8.6.8.2. Rest of Middle East & Africa: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
      • 8.6.8.3. Rest of Middle East & Africa: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • 8.7. Plasma Protease C1-inhibitor Market - Latin America
    • 8.7.1. Latin America: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
    • 8.7.2. Latin America.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
    • 8.7.3. Latin America: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
    • 8.7.4. Plasma Protease C1-inhibitor Market - Mexico
      • 8.7.4.1. Mexico: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
      • 8.7.4.2. Mexico.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
      • 8.7.4.3. Mexico: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
    • 8.7.5. Plasma Protease C1-inhibitor Market - Brazil
      • 8.7.5.1. Brazil: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
      • 8.7.5.2. Brazil.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
      • 8.7.5.3. Brazil: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
    • 8.7.6. Plasma Protease C1-inhibitor Market - Argentina
      • 8.7.6.1. Argentina: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
      • 8.7.6.2. Argentina.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
      • 8.7.6.3. Argentina: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
    • 8.7.7. Plasma Protease C1-inhibitor Market - Rest of Latin America
      • 8.7.7.1. Rest of Latin America: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
      • 8.7.7.2. Rest of Latin America.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
      • 8.7.7.3. Rest of Latin America: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. BioCryst Pharmaceuticals, Inc.
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. CENTOGENE N.V.
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. CSL
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Fresenius Kabi
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Ionis Pharmaceuticals, Inc.
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. KalVista Pharmaceuticals
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Pharming
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Sanquin
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Shire plc
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Takeda Pharmaceutical Company Limited
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development

List of Tables

  • Table 1 Global Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
  • Table 2 Global Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • Table 3 Global Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
  • Table 4 Plasma Protease C1-inhibitor Market Assessment, By Geography, 2019-2032 (USD billion)
  • Table 5 North America: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
  • Table 6 North America: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • Table 7 North America: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
  • Table 8 U.S.: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
  • Table 9 U.S.: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • Table 10 U.S.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
  • Table 11 Canada: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
  • Table 12 Canada: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • Table 13 Canada: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
  • Table 14 Europe: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
  • Table 15 Europe: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • Table 16 Europe: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
  • Table 17 UK: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
  • Table 18 UK: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • Table 19 UK: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
  • Table 20 France: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
  • Table 21 France: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • Table 22 France: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
  • Table 23 Germany: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
  • Table 24 Germany: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • Table 25 Germany: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
  • Table 26 Italy: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
  • Table 27 Italy: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • Table 28 Italy: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
  • Table 29 Spain: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
  • Table 30 Spain: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • Table 31 Spain: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
  • Table 32 Netherlands: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
  • Table 33 Netherlands: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • Table 34 Netherlands: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
  • Table 35 Russia: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
  • Table 36 Russia: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • Table 37 Russia: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
  • Table 38 Rest of Europe: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
  • Table 39 Rest of Europe: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • Table 40 Rest of Europe: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
  • Table 41 Asia Pacific: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
  • Table 42 Asia Pacific: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • Table 43 Asia Pacific: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
  • Table 44 China: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
  • Table 45 China: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • Table 46 China: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
  • Table 47 India: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
  • Table 48 India: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • Table 49 India: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
  • Table 50 Malaysia: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
  • Table 51 Malaysia: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • Table 52 Malaysia: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
  • Table 53 Japan: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
  • Table 54 Japan: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • Table 55 Japan: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
  • Table 56 Indonesia: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
  • Table 57 Indonesia: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • Table 58 Indonesia: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
  • Table 59 South Korea: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
  • Table 60 South Korea: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • Table 61 South Korea: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
  • Table 62 Australia: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
  • Table 63 Australia: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • Table 64 Australia: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
  • Table 65 Rest of Asia Pacific: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
  • Table 66 Rest of Asia Pacific: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • Table 67 Rest of Asia Pacific: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
  • Table 68 Middle East & Africa: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
  • Table 69 Middle East & Africa: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • Table 70 Middle East & Africa: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
  • Table 71 Saudi Arabia: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
  • Table 72 Saudi Arabia: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • Table 73 Saudi Arabia: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
  • Table 74 UAE: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
  • Table 75 UAE: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • Table 76 UAE: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
  • Table 77 Israel: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
  • Table 78 Israel: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • Table 79 Israel: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
  • Table 80 South Africa: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
  • Table 81 South Africa: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • Table 82 South Africa: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
  • Table 83 Rest of Middle East & Africa: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
  • Table 84 Rest of Middle East & Africa: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • Table 85 Rest of Middle East & Africa: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
  • Table 86 Latin America: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
  • Table 87 Latin America: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • Table 88 Latin America: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
  • Table 89 Mexico: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
  • Table 90 Mexico: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • Table 91 Mexico: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
  • Table 92 Brazil: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
  • Table 93 Brazil: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • Table 94 Brazil: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
  • Table 95 Argentina: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
  • Table 96 Argentina: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • Table 97 Argentina: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
  • Table 98 Rest of Latin America: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
  • Table 99 Rest of Latin America: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • Table 100 Rest of Latin America: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)

List of Figures

  • Figure 1. Global Plasma Protease C1-inhibitor Market, 2019-2032 (USD billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Distribution Channel
  • Figure 7. Global Plasma Protease C1-inhibitor Market, by Distribution Channel, 2023 & 2032 (USD billion)
  • Figure 8. Market by Drug Class
  • Figure 9. Global Plasma Protease C1-inhibitor Market, by Drug Class, 2023 & 2032 (USD billion)
  • Figure 10. Market by Dosage Form
  • Figure 11. Global Plasma Protease C1-inhibitor Market, by Dosage Form, 2023 & 2032 (USD billion)
  • Figure 12. Plasma Protease C1-inhibitor Market Assessment, By Geography, 2019-2032 (USD billion)
  • Figure 13. Strategic Analysis - Plasma Protease C1-inhibitor Market